Mazdutide vs Tirzepatide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicMazdutideTirzepatide
What it is

A glucagon and GLP-1 receptor agonist developed by Innovent Biologics (IBI362) and studied by Eli Lilly (LY3305677).6,7,8

A GIP receptor and GLP-1 receptor agonist. The Zepbound label states that it selectively binds to and activates both receptors.3

FDA status

Approval reported abroad

China: approval reported by local government sources1,2

Not FDA-approved. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels. Suzhou government reports describe approval in China in 2025.1,2,9

Is mazdutide approved?

FDA-approved

FDA-approved as Mounjaro and Zepbound3,4,5

FDA-approved. Drugs@FDA lists Mounjaro (first approved May 13, 2022) and Zepbound (November 8, 2023). The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats.3,4,5

Is tirzepatide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.10

Not among the six peptides the policy lists.10

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial GLORY-1 (NCT05607680): a randomized, double-blind, placebo-controlled Phase 3 trial in 610 adults in China with overweight or obesity, published in The New England Journal of Medicine.6
  • Large randomized human trial A 28-week randomized Phase 3 trial in 731 adults in China with type 2 diabetes that compared mazdutide with dulaglutide, published in Nature.11
  • Controlled human trial A randomized, placebo-controlled Phase 2 trial in 179 adults in the United States with overweight or obesity.12

Large randomized human trials

  • Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04184622) that enrolled 2,539 adults with obesity, or overweight with a weight-related condition, and excluded type 2 diabetes.3
  • Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04657003) in 938 adults with type 2 diabetes and overweight or obesity.3
  • Controlled human trial Two 52-week randomized, double-blind, placebo-controlled sleep apnea trials (NCT05412004) that together enrolled 469 adults with obesity.3
  • Large randomized human trial SURPASS-CVOT, which compared tirzepatide with dulaglutide on major adverse cardiovascular events in people with type 2 diabetes. FDA’s August 2026 letter cites it as the basis for the new Mounjaro indication.13,14
Records collected

16 ClinicalTrials.gov records and 5 PubMed records collected

108 ClinicalTrials.gov records and 75 PubMed records collected

Area of study

Metabolic and weight1,2

Metabolic and weight3

Latest dated events
  1. FDA’s page on unapproved GLP-1 drugs, which names mazdutide, is updated, as shown by its content-current date.9
  2. ClinicalTrials.gov lists Eli Lilly’s Phase 2 trial in the United States as completed.8
  3. A Suzhou government report describes approved diabetes and weight-management uses in China.2
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.9
  2. DailyMed publishes the Zepbound label version cited on this page.3
  3. FDA approves a new Mounjaro indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk.13

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    June 27, 2025 government report of Chinese approval for mazdutide weight management ↗

    Suzhou Industrial Park Market Supervision Bureau · Official source · Source checked September 15, 2026

  2. 2
    December 19, 2025 government report describing Chinese mazdutide diabetes and weight indications ↗

    Suzhou Municipal Government · Official source · Source checked September 15, 2026

  3. 3
    ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  4. 4
    Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1, 2025) · PMID 40421736 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  7. 7
    ClinicalTrials.gov record NCT07469800 · retained source version 2026-05-27:81ca4ac5542c9dd986eb9ee84eec93f13dc03f4151273b5eb069ff56c5baf9ac ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  8. 8
    ClinicalTrials.gov record NCT06124807 · retained source version 2026-04-21:5c8024d2506081c76bbe43d846c2785e0fea51ea4fcaad5871b2b0dacb114691 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  9. 9
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  10. 10
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  11. 11
    Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes (2025) · PMID 41407860 ↗

    Nature · Official source · Source checked November 14, 2026

  12. 12
    Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial (2026) · PMID 42628555 ↗

    The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026

  13. 13
    Mounjaro (tirzepatide): NDA 215866 supplements S-044 and S-045 approval letter, August 27, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  14. 14
    Zepbound (tirzepatide): NDA 217806 supplement S-041 corrected approval letter, effective August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026